Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down
While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.
You may also be interested in...
The company will focus on core therapeutics areas like oncology and cardiovascular disease, but left open the possibility of future work in neuroscience with a genetic basis for drug development.
The French biotech’s lead drug candidate has suffered a clinical-stage setback in narcolepsy, but the Paris-quoted firm is hoping that a Parkinson’s study will give more traction to its pipeline of CNS disease candidates.
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.